Activest Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Activest Wealth Management's CRSP Position: Q3 2026 in Review
Activest Wealth Management reduced its CRISPR Therapeutics (CRSP) stake by 79% in Q3 2026, selling an estimated $594 and leaving 3 shares worth $166. The position accounts for ﹤0.01% of the portfolio, ranked #984.
Activest Wealth Management first reported a position in CRSP in Q4 2024 and has held it in 3 quarters since. The position peaked at $764 in Q2 2026. 500 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Activest Wealth Management held 3 shares of CRISPR Therapeutics worth $166 as of Q3 2026.
- Activest Wealth Management sold 11 CRISPR Therapeutics shares in Q3 2026, an estimated $594.
- CRISPR Therapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q3 2026, its #984 holding.
- Activest Wealth Management first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 3 quarters since.
- Activest Wealth Management's CRISPR Therapeutics position peaked at $764 in Q2 2026.
- 500 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.